We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Barr Pharmaceuticals has received a license from drugmaker Cephalon to market a generic version of Cephalon’s cancer pain treatment Actiq (oral transmucosal fentanyl citrate).